Skip to main content
. 2022 Oct 6;10(28):10004–10016. doi: 10.12998/wjcc.v10.i28.10004

Table 3.

Protective effect of astragaloside IV on lung disease

Disease categories
Study object/model
Effect induced by autophagy
Mechanism (targets or pathways)
Ref.
Lung injury PM2.5-induced lung toxicity in rats (-) PM2.5-induced lung toxicity; (+) autophagic flux (+) AMPK/mTOR pathway Wang et al[36]
Lung injury PM2.5 in rats and rat alveolar macrophages (-) Severe inflammation and oxidative stress, (+) autophagic flux mainly via autophagosome degradation (-) The PI3K/Akt/mTOR pathway to (+) autophagy and (-) inflammation Pei et al[37]
Lung injury LPS in pulmonary epithelial cell (-) Apoptosis in cell model, (-) autophagy initiation (-) The oxidative stress and inflammatory response Liu et al[34]
Lung adenocarcinoma Bevacizumab in A549 cells (-) Proliferation inhibition and apoptosis promotion (-) inhibiting autophagy pathway Autophagy-related proteins (p62, LC3 II/LC3 I), p-AKT and p-Mtor Li et al[57]
NSCLC Cisplatin-resistant the NSCLC cell lines (-) Chemoresistance to cisplatin in NSCLC cells via (-) inhibition of ER stress or autophagy Autophagy-related proteins (Beclin1, LC3 II/I) Lai et al[35]

AMPK: AMP-activated protein kinase; LPS: Lipopolysaccharide; LC: Lung cancer; NSCLC: Non-small cell lung cancer; ER: Endoplasmic reticulum